Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1600 1632 1635 1637 1674
This examiner grants 65% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18304519 | Compositions and Methods for Treating Spinal Muscular Atrophy | Non-Final OA | Genzyme Corporation |
| 17375785 | METHODS AND COMPOSITIONS FOR TREATING A SERPINC1-ASSOCIATED DISORDER | Final Rejection | Genzyme Corporation |
| 17855053 | Methods Of Treating Decreased Bone Mineral Density With Kringle Containing Transmembrane Protein 1 (KREMEN1) Inhibitors | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 19245022 | COMPOSITIONS AND METHODS FOR INHIBITION OF EXPRESSION OF INHIBIN SUBUNIT BETA E (INHBE) GENES | Non-Final OA | BASECURE THERAPEUTICS LLC |
| 18007609 | NUCLEIC ACID MOLECULE HAVING IMPROVED STABILITY, AND USE THEREOF | Non-Final OA | RESEARCH & BUSINESS FOUNDATION SUNGKYUNKWAN UNIVERSITY |
| 18382562 | METHODS OF TREATING TRANSTHYRETIN (TTR) MEDIATED AMYLOIDOSIS | Non-Final OA | Alnylam Pharmaceuticals, Inc. |
| 18302855 | METHODS AND COMPOSITIONS FOR TREATING PRIMARY HYPEROXALURIA | Non-Final OA | Alnylam Pharmaceuticals, Inc. |
| 18125167 | DIPEPTIDYL PEPTIDASE 4 (DPP4) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | Non-Final OA | Alnylam Pharmaceuticals, Inc. |
| 17907664 | COMPOSITIONS AND METHODS FOR SILENCING DNAJC15 GENE EXPRESSION | Non-Final OA | ALNYLAM PHARMACEUTICALS, INC. |
| 17664032 | METHODS AND COMPOSITIONS FOR TREATING MALIGNANT TUMORS ASSOCIATED WITH KRAS MUTATION | Final Rejection | Nitto Denko Corporation |
| 17938209 | BAG3 AS A TARGET FOR THERAPY OF HEART FAILURE | Non-Final OA | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION |
| 17930088 | RIBONUCLEOPROTEINS FOR RNA THERAPEUTICS DELIVERY AND GENE SILENCING | Final Rejection | Hong Kong Baptist University |
| 18247152 | METHODS OF TREATING VIRAL INFECTIONS WITH PiRNAS OR EXTRACELLULAR VESSICLES RELEASED FROM NEURAL STEM CELLS OR NEURAL PROGENITOR CELLS | Non-Final OA | Albert Einstein College of Medicine |
| 17919459 | COMPOSITIONS AND METHODS FOR INHIBITING TDP-43 AND FUS AGGREGATION | Non-Final OA | THE UNIVERSITY OF BRITISH COLUMBIA |
| 18247567 | METHODS FOR REDUCING APOCIII EXPRESSION | Non-Final OA | IONIS PHARMACEUTICALS, INC. |
| 18001848 | COMPOUNDS AND METHODS FOR MODULATING PMP22 | Non-Final OA | Ionis Pharmaceuticals, Inc. |
| 17802324 | COMPOUNDS AND METHODS FOR MODULATING SCN1A EXPRESSION | Non-Final OA | Ionis Pharmaceuticals, Inc. |
| 17372173 | MODULATION OF APOLIPOPROTEIN C-III (APOCIII) EXPRESSION IN LIPOPROTEIN LIPASE DEFICIENT (LPLD) POPULATIONS | Final Rejection | Ionis Pharmaceuticals, Inc. |
| 18132278 | Polynucleotides, Compositions, and Methods for Genome Editing | Final Rejection | Intellia Therapeutics, Inc. |
| 18126145 | NUCLEOSIDE CONTAINING siRNAS FOR TREATING VIRAL DISEASES | Non-Final OA | Sirnaomics, Inc. |
| 17720676 | OLIGONUCLEOTIDES COMPRISING A PHOSPHORODITHIOATE INTERNUCLEOSIDE LINKAGE | Non-Final OA | ROCHE INNOVATION CENTER COPENHAGEN A/S |
| 18256707 | APTAMER-siRNA FUSIONS | Non-Final OA | APTERNA LIMITED |
| 18130418 | Target Ligand | Non-Final OA | NANOPEPTIDE (QINGDAO) BIOTECHNOLOGY LTD. |
| 18092202 | SIRNA OF ANGPTL3 AND USE THEREOF | Non-Final OA | NANOPEPTIDE (QINGDAO) BIOTECHNOLOGY LTD. |
| 18027883 | CANCER THERAPY USING TOLL-LIKE RECEPTOR AGONISTS | Non-Final OA | TriSalus Life Sciences, Inc. |
| 18006284 | METHODS AND COMPOSITIONS FOR TREATING CANCER | Non-Final OA | PROMETTRE RESEARCH PTY LTD |
| 17792746 | METHODS AND COMPOSITIONS FOR THE INHIBITION OF HEPATITIS B AND HEPATITIS D VIRUS INFECTIONS | Non-Final OA | REPLICOR INC. |
| 17832182 | ANTISENSE OLIGOMERS FOR TREATMENT OF CONDITIONS AND DISEASES | Final Rejection | Stoke Therapeutics, Inc. |
| 16908540 | Methods of Novel Therapeutic Candidate Identification Through Gene Expression Analysis in Vascular-Related Diseases | Non-Final OA | Vascular Biosciences |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy